{
    "title": "114_s483",
    "content": "SECTION 1. SHORT TITLE.\n    This Act may be cited as the ``Ensuring Patient Access and \nEffective Drug Enforcement Act of 2016''.\nSEC. 2. REGISTRATION PROCESS UNDER CONTROLLED SUBSTANCES ACT.\n    (a) Definitions.--\n        (1) Factors as may be relevant to and consistent with the \n    public health and safety.--Section 303 of the Controlled Substances \n    Act (21 U.S.C. 823) is amended by adding at the end the following:\n    ``(j) In this section, the phrase `factors as may be relevant to \nand consistent with the public health and safety' means factors that \nare relevant to and consistent with the findings contained in section \n101.''.\n        (2) Imminent danger to the public health or safety.--Section \n    304(d) of the Controlled Substances Act (21 U.S.C. 824(d)) is \n    amended--\n            (A) by striking ``(d) The Attorney General'' and inserting \n        ``(d)(1) The Attorney General''; and\n            (B) by adding at the end the following:\n    ``(2) In this subsection, the phrase `imminent danger to the public \nhealth or safety' means that, due to the failure of the registrant to \nmaintain effective controls against diversion or otherwise comply with \nthe obligations of a registrant under this title or title III, there is \na substantial likelihood of an immediate threat that death, serious \nbodily harm, or abuse of a controlled substance will occur in the \nabsence of an immediate suspension of the registration.''.\n    (b) Opportunity To Submit Corrective Action Plan Prior to \nRevocation or Suspension.--Subsection (c) of section 304 of the \nControlled Substances Act (21 U.S.C. 824) is amended--\n        (1) by striking the last three sentences;\n        (2) by striking ``(c) Before'' and inserting ``(c)(1) Before''; \n    and\n        (3) by adding at the end the following:\n    ``(2) An order to show cause under paragraph (1) shall--\n        ``(A) contain a statement of the basis for the denial, \n    revocation, or suspension, including specific citations to any laws \n    or regulations alleged to be violated by the applicant or \n    registrant;\n        ``(B) direct the applicant or registrant to appear before the \n    Attorney General at a time and place stated in the order, but not \n    less than 30 days after the date of receipt of the order; and\n        ``(C) notify the applicant or registrant of the opportunity to \n    submit a corrective action plan on or before the date of \n    appearance.\n    ``(3) Upon review of any corrective action plan submitted by an \napplicant or registrant pursuant to paragraph (2), the Attorney General \nshall determine whether denial, revocation, or suspension proceedings \nshould be discontinued, or deferred for the purposes of modification, \namendment, or clarification to such plan.\n    ``(4) Proceedings to deny, revoke, or suspend shall be conducted \npursuant to this section in accordance with subchapter II of chapter 5 \nof title 5, United States Code. Such proceedings shall be independent \nof, and not in lieu of, criminal prosecutions or other proceedings \nunder this title or any other law of the United States.\n    ``(5) The requirements of this subsection shall not apply to the \nissuance of an immediate suspension order under subsection (d).''.\nSEC. 3. REPORT TO CONGRESS.\n    (a) In General.--Not later than 1 year after the date of enactment \nof this Act, the Secretary of Health and Human Services, acting through \nthe Commissioner of Food and Drugs, the Administrator of the Substance \nAbuse and Mental Health Services Administration, the Director of the \nAgency for Healthcare Research and Quality, and the Director of the \nCenters for Disease Control and Prevention, in coordination with the \nAdministrator of the Drug Enforcement Administration and in \nconsultation with the Secretary of Defense and the Secretary of \nVeterans Affairs, shall submit a report to the Committee on the \nJudiciary of the House of Representatives, the Committee on Energy and \nCommerce of the House of Representatives, the Committee on the \nJudiciary of the Senate, and the Committee on Health, Education, Labor, \nand Pensions of the Senate identifying--\n        (1) obstacles to legitimate patient access to controlled \n    substances;\n        (2) issues with diversion of controlled substances;\n        (3) how collaboration between Federal, State, local, and tribal \n    law enforcement agencies and the pharmaceutical industry can \n    benefit patients and prevent diversion and abuse of controlled \n    substances;\n        (4) the availability of medical education, training \n    opportunities, and comprehensive clinical guidance for pain \n    management and opioid prescribing, and any gaps that should be \n    addressed;\n        (5) beneficial enhancements to State prescription drug \n    monitoring programs, including enhancements to require \n    comprehensive prescriber input and to expand access to the programs \n    for appropriate authorized users; and\n        (6) steps to improve reporting requirements so that the public \n    and Congress have more information regarding prescription opioids, \n    such as the volume and formulation of prescription opioids \n    prescribed annually, the dispensing of such prescription opioids, \n    and outliers and trends within large data sets.\n    (b) Consultation.--The report under subsection (a) shall \nincorporate feedback and recommendations from the following:\n        (1) Patient groups.\n        (2) Pharmacies.\n        (3) Drug manufacturers.\n        (4) Common or contract carriers and warehousemen.\n        (5) Hospitals, physicians, and other health care providers.\n        (6) State attorneys general.\n        (7) Federal, State, local, and tribal law enforcement agencies.\n        (8) Health insurance providers and entities that provide \n    pharmacy benefit management services on behalf of a health \n    insurance provider.\n        (9) Wholesale drug distributors.\n        (10) Veterinarians.\n        (11) Professional medical societies and boards.\n        (12) State and local public health authorities.\n        (13) Health services research organizations.\n\n                               Speaker of the House of Representatives.\n\n                            Vice President of the United States and    \n                                               President of the Senate."
}